Who
Corleen M. Roche
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Iovance Biotherapeutics; CFO, CG Oncology; Chief Financial Officer, Immunome.
In numbers
- Trades disclosed
- 18
- Buys
- 1
- Sells
- 0
- Bought
- $38K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 19 Apr 2021
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —49,995 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $132K21,238 at $6.21 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,995 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,995 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —49,995 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $132K21,238 at $6.21 | filing |
| 9 Mar 2026filed 11 Mar 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,200 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,200 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Apr 2025filed 16 Apr 2025 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —143,907 at $0.00 | filing |
| 4 Oct 2024filed 8 Oct 2024 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,600 at $0.00 | filing |
| 29 Jan 2024filed 31 Jan 2024 | CGON CG OncologyBiotechnology | SEC FORM 4 Bought | $38K2,000 at $19.00 | filing |
| 24 Jan 2024filed 26 Jan 2024 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —492,920 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —58,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 28 May 2021filed 1 Jun 2021 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,609 at $0.00 | filing |
| 19 Apr 2021filed 21 Apr 2021 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
News
Head to Head Contrast: CG Oncology (NASDAQ:CGON) and Myriad Genetics (NASDAQ:MYGN)CGON · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Corleen M. Roche; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.